Moderna, Inc. - Common Stock (MRNA)

The healthcare stock has generated massive returns this year and may still have room to rise even higher in the future.

Stéphane Bancel has high hopes for the company's cancer vaccine, beyond just treating melanoma.

Moderna stock has skyrocketed this year.

These biotechs’ valuations are through the roof.

Moderna shares have outperformed tech giants this year.

Axsome's steady ascent has flipped the script—it now outpaces Moderna in quarterly revenue despite starting from a fraction of its size.

Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply while Merck stock barely moved.

Moderna (NASDAQ:MRNA) presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with Merck’s pembrolizumab for patients with resected high-risk melanoma. The INTerpath-001 trial met its primary endpoint of relapse-free survival and a key secondary endpoint of di

The stock fell 17% in one trading session.

Personalized cancer vaccine material allegedly circulated online ahead of formal Phase 3 results, today, Oct. 22, 2026.

What happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 22.7% in the afternoon session after the company's partial Phase 3 data for its per...

The market has rewarded this biotech for its breakthroughs.

This company made headlines with its coronavirus vaccine.

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...

What Happened? A number of stocks jumped in the afternoon session after investors rotated into defensive assets and priced in rising expectations that midter...